Scroll To Top
News

A Boost for Boosting

A Boost for Boosting

51_coverx100_20

Are you prone to missing doses of your antiretroviral drugs? If so, a Norvir-boosted protease inhibitor may be a good choice for you. A new Canadian study of 1,630 HIVers examining the links among treatment failure, specific anti-HIV drugs, and adherence has found that adherence of less than 95% significantly raised the risk of treatment failure for people taking an unboosted protease inhibitor or nonnucleoside drugs. But there was no increased risk seen among people on boosted protease inhibitor regimens. Norvir-boosted protease inhibitors remain at therapeutic levels in the body longer than other anti-HIV drugs, making an occasional delayed or missed dose unlikely to result in a loss of virological control and the emergence of drug resistance, according to the researchers. 'For individuals at high risk of suboptimal adherence, using boosted protease inhibitor'based regimens may achieve higher effectiveness rates,' they conclude.

Advocate Channel - The Pride StoreOut Magazine - Fellow Travelers

From our Sponsors

Most Popular

Latest Stories

Plus Editors

Editor

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.

Ryan is the Digital Director of The Advocate Channel, and a graduate of NYU Tisch's Department of Dramatic Writing. She is also a member of GALECA, the LGBTQ+ society of entertainment critics. While her specialties are television writing and comedy, Ryan is a young member of the LGBTQ+ community passionate about politics and advocating for all.